[Complications observed in the treatment of trypanosomiasis in the Congo].
The authors present the results obtained in the treatment of 453 sleeping sickness (T. gambiense) patients in the People's Republic of the Congo. They give the following conclusions: The mortality rate reaches 2,75% in the group of patients treated by melarsoprol and is nil in the group treated with pentamidin. The encephalitis rate is 2,1 per 100 series of melarsoprol. The treatment of encephalopathies with adrenaline according to the protocol of SINA gives very good results and should be generalized.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D020261:Arsenic Poisoning; D001152:Arsenicals / Q000009:adverse effects*; D001927:Brain Diseases / Q000139:chemically induced* / Q000188:drug therapy; D003223:Congo; D004660:Encephalitis / Q000139:chemically induced / Q000188:drug therapy; D004837:Epinephrine / Q000627:therapeutic use; D006801:Humans; D008549:Melarsoprol / Q000009:adverse effects*; D010400:Penicillin G / Q000627:therapeutic use; D010419:Pentamidine / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D014347:Trypanosoma brucei gambiense; D014353:Trypanosomiasis, African / Q000188:drug therapy* / Q000401:mortality; D014815:Vitamins / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D001152:Arsenicals; D014815:Vitamins; D010419:Pentamidine; D010400:Penicillin G; D011241:Prednisone; D004837:Epinephrine; D008549:Melarsoprol
Accidents observés lors du traitement de la trypanosomiase au Congo.